FindTrial
Sign In

NKTR-255

DRUG5 trials

Sponsors

Stanford University, Nektar Therapeutics, EMD Serono Research & Development Institute, Inc., M.D. Anderson Cancer Center

Conditions

B Acute Lymphoblastic LeukemiaCD19 PositiveColorectal CancerHead and Neck Squamous Cell CarcinomaIndolent Non-Hodgkin LymphomaLocally Advanced or Metastatic Urothelial CarcinomaLung CancerMinimal Residual Disease

Phase 1

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Active, not recruitingNCT03233854
Stanford UniversityB Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease +1
Start: 2017-09-01End: 2035-09-01Updated: 2025-11-18
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
CompletedNCT04136756
Nektar TherapeuticsIndolent Non-Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma
Start: 2019-10-07End: 2023-04-24Updated: 2023-06-15
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
CompletedNCT04616196
Nektar TherapeuticsColorectal Cancer, Head and Neck Squamous Cell Carcinoma
Start: 2020-10-30End: 2023-03-30Updated: 2025-06-08

Phase 2

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
Active, not recruitingNCT05327530
EMD Serono Research & Development Institute, Inc.Locally Advanced or Metastatic Urothelial Carcinoma
Start: 2022-08-17End: 2026-06-25Updated: 2026-01-26
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)
RecruitingNCT05632809
M.D. Anderson Cancer CenterLung Cancer
Start: 2023-01-10End: 2027-12-31Target: 39Updated: 2026-03-11

Related Papers

Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL
Blood2025-11-03
Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial.
Journal of Clinical Oncology2025-05-282 citations
TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial
Journal for ImmunoTherapy of Cancer2025-02-015 citations
Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
Blood2024-11-052 citations
CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL
Blood2024-11-051 citations
NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Blood2024-11-051 citations
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
Blood2024-07-0519 citations
Abstract CT184: First-in-human trial of TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa (BA) in patients (pts) with advanced solid unresectable tumors
Cancer Research2024-04-051 citations
Abstract 6325: Lineage tracing defines responding CAR T cells in patients with B cell malignancies
Cancer Research2024-03-22
The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma
Future Oncology2023-09-0612 citations
Abstract 1128: Lineage tracing of CAR T cells in patients with B cell malignancies
Cancer Research2023-04-042 citations
A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Blood2022-11-152 citations
A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Blood2022-11-151 citations
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
Blood Advances2022-11-0422 citations
665 JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma
Regular and Young Investigator Award Abstracts2022-11-014 citations
432 Evaluation of novel anti-TIGIT antibody M6223 as a single agent and in combination with avelumab on human natural killer (NK) cell cytotoxicity
Regular and Young Investigator Award Abstracts2022-11-012 citations
497 Evaluation of the TIGIT+ immune subset depletion effect of the anti-TIGIT antibody M6223
Regular and Young Investigator Award Abstracts2022-11-011 citations
Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8 + T-Cells: Preliminary Results from a Phase 1 Study
Blood2021-11-055 citations
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
Blood2021-11-054 citations
957 NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study
2021-11-016 citations

3 more papers not shown